Nanjing Hicin Pharmaceutical Co., Ltd. (SHE:300584)
37.90
+0.02 (0.05%)
Jul 3, 2026, 3:04 PM CST
SHE:300584 Revenue
Nanjing Hicin Pharmaceutical had revenue of 160.34M CNY in the quarter ending March 31, 2026, with 12.40% growth. This brings the company's revenue in the last twelve months to 688.74M, up 26.97% year-over-year. In the year 2025, Nanjing Hicin Pharmaceutical had annual revenue of 671.05M with 33.05% growth.
Revenue (ttm)
688.74M
Revenue Growth
+26.97%
P/S Ratio
6.60
Revenue / Employee
1.25M
Employees
553
Market Cap
4.55B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 671.05M | 166.69M | 33.05% |
| Dec 31, 2024 | 504.36M | -13.47M | -2.60% |
| Dec 31, 2023 | 517.83M | -8.63M | -1.64% |
| Jan 1, 2023 | 526.47M | -51.85M | -8.97% |
| Jan 1, 2022 | 578.32M | -127.98M | -18.12% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Lianhuan Pharmaceutical | 2.89B |
| Zhejiang Starry Pharmaceutical | 2.47B |
| Luoxin Pharmaceuticals Group Stock | 2.37B |
| Tianjin Lisheng Pharmaceutical | 1.35B |
| Bide Pharmatech | 1.35B |
| Shanghai Kaibao Pharmaceutical CO.,Ltd | 1.04B |
| Zhongzhu Healthcare Holding Co.,Ltd | 544.73M |
| Heilongjiang ZBD Pharmaceutical | 509.95M |